Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
154.70
-4.68 (-2.94%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
170,761
Open
158.39
Bid (Size)
151.00 (1)
Ask (Size)
159.00 (1)
Prev. Close
159.38
Today's Range
152.71 - 159.47
52wk Range
126.97 - 225.23
Shares Outstanding
1,211,067,023
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
June 17, 2024
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for...
Via
Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
June 15, 2024
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...
Via
Talk Markets
Performance
YTD
-12.60%
-12.60%
1 Month
-11.26%
-11.26%
3 Month
-8.19%
-8.19%
6 Month
-15.21%
-15.21%
1 Year
-19.25%
-19.25%
More News
Read More
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
June 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
Evaluating BeiGene: Insights From 6 Financial Analysts
April 24, 2024
Via
Benzinga
4 Analysts Assess BeiGene: What You Need To Know
March 27, 2024
Via
Benzinga
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in 3/13 Morning Trading
March 13, 2024
Via
Investor Brand Network
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
BeiGene, Ltd.
Via
Business Wire
7 Large-Cap Stocks That Can Jump 50% By 2025
May 29, 2024
Via
InvestorPlace
Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio?
May 26, 2024
Via
Benzinga
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
May 25, 2024
Via
Talk Markets
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
May 24, 2024
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
May 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
BGNE Stock Earnings: BeiGene Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
Via
InvestorPlace
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
May 08, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
April 28, 2024
Via
Benzinga
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
April 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
April 24, 2024
From
BeiGene, Ltd.
Via
Business Wire
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
April 23, 2024
Via
Benzinga
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
April 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
March 30, 2024
Via
Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Via
Talk Markets
Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
March 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
March 15, 2024
Via
Benzinga
Exposures
Product Safety
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
March 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.